By explaining the mechanisms through which ARID1A mutations influence tumor behavior and immune interactions, researchers can address unique characteristics of both ER+ and ER- breast cancers, enhancing the precision of oncology and improving patient outcomes. The gene discussed is ESR1; the disease is breast carcinoma.